ClinicalTrials.gg
RecruitingNCT07523581Updated Sep 30, 2026

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

A Phase 2 interventional study of Exaluren in Alport Syndrome, X-Linked and Alport Syndrome, Autosomal Recessive, sponsored by Eloxx Pharmaceuticals, Inc.. Recruiting at 11 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Sep 30, 2026Eligibility revised1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Nephritis, Hereditary with a site in United States — 5 open to participants now, 8 under way, none of them phase 3. Nephritis, Hereditary · United States.

Planned enrollment
10th of 11
24 · median 60
Started
2026
with 1 other
Phase 2
7 of 19
2 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Eloxx Pharmaceuticals, Inc.

Among the 19 studies in Nephritis, Hereditary with a site in United States, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 2, and was the 18th registered.

Nephritis, Hereditary

39 studies on the registry are indexed under Nephritis, Hereditary; 15 are open to participants now.

Browse Nephritis, Hereditary studies →

Open to participants now

5 of the 19 studies in Nephritis, Hereditary with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Nephritis, Hereditary studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Nephritis, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes.

Targeted 24 patients aged 12 and older will be enrolled in the trial.

The study will be comprised of the following periods for each participant:

  • a Screening period of up to 6 weeks (42 days)
  • a total Treatment Period of exaluren 0.75 mg/kg or placebo administered daily subcutaneously for 32 weeks: Part 1: patients are randomized to either exaluren or placebo for 16 weeks. Part 2: all patients across both randomized arms receive exaluren for 16 additional weeks.
  • a safety/efficacy Follow-up Period of 4 weeks after the last treatment
03

Conditions studied

  • Alport Syndrome, X-Linked
  • Alport Syndrome, Autosomal Recessive

Browse trials for

Keywords

  • Nonsense Mutation
  • Translational read through
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A confirmed diagnosis of X-linked or autosomal recessive Alport Syndrome with a documented nonsense mutation of COL4A5 in a male or nonsense mutation of COL4A3 or COL4A4 (male or female)
  • >40 ml/min/1.73 m2
  • Urinary protein based on two spot urine collections [urine protein/creatinine ratio (UPCR) ≥ 300 mg/g]
  • Stable regimen of ACEi/ARB for at least 12 weeks before Day 1

Exclusion criteria

Exclusion Criteria:

  • History of any organ transplantation
  • Liver disease characterized by cirrhosis or portal hypertension. Participants with (ALT), aspartate aminotransferase (AST), and/or a total 1.5 times the (ULN) will be excluded
  • History of dialysis
  • Acute kidney injury within 4 weeks before screening
  • Active dizziness
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Exaluren

    Drug: Exaluren

  • Placebo comparator
    Placebo

    Drug: Exaluren

Interventions

  • Exaluren is a synthetic Eukaryotic Ribosome Selective Glycoside (ERSG)

06

What researchers measure

Primary outcomes

  1. The change in the degree of podocyte foot process effacement

    Measured in kidney biopsies by the change in the Filtration Slit Density (FSD)

    Time frame: Baseline to Week 16

  2. The change in the degree of podocyte foot process effacement

    Measured in kidney biopsies by the change in the Filtration Slit Density (FSD)

    Time frame: Baseline to Week 32

Secondary outcomes

  1. The percentage change in Urine Protein Creatinine Ratio (UPCR)

    Calculated from geometric mean of 3 consecutive days of first void urine collection

    Time frame: Baseline to Week 16

  2. The percentage change in Urine Protein Creatinine Ratio (UPCR)

    Calculated from geometric mean of 3 consecutive days of first void urine collection

    Time frame: Baseline to Week 32

Other outcomes

  1. The percentage change in estimated Glomerular Filtration Rate (eGFR)

    Change in eGFR level

    Time frame: Baseline to Week 16 and Week 32

  2. The change in the degree of podocyte foot process effacement

    Measured by the change in Foot Process Width (FPW)

    Time frame: Baseline to Week 16 and Week 32

  3. The change in collagen expression

    Measured by structural changes

    Time frame: Baseline to Week 16 and Week 32

  4. Evaluate the safety and tolerability of Exaluren

    The incidence and characteristics of adverse events (AEs)

    Time frame: Screening to End of Study (Week 36)

07

Study locations

3 of 11 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2026
First posted
Apr 13, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Cleveland Clinic · Cleveland, United States
Sep 30, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedeGFR>4540 ml/min/1.73 m2
  • EditedUrinary protein based on two spot urine collections [urine protein/creatinine ratio (UPCR) ≥ 500300 mg/g]
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site removed
    Show 1 removed
    • Cleveland Clinic · Cleveland, United States
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedeGFR>4540 ml/min/1.73 m2
    • EditedUrinary protein based on two spot urine collections [urine protein/creatinine ratio (UPCR) ≥ 500300 mg/g]
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07523581
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Jun 30, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ELX-02

Start the discussion